United States Welcomes Arrival of Groundbreaking HIV Prevention Medicine in South Africa
This image was generated by AI and may not depict real events.
The United States has announced a $115 million bridging plan to continue funding HIV treatment and prevention programs in South Africa until March 2026. South Africa is set to roll out a new long-acting antiretroviral drug called Lenacapavir, which offers six months of continuous protection per dose and has shown remarkable efficacy in preventing HIV.
The US has announced a $115 million plan to fund HIV treatment and prevention in South Africa. This plan will last from October 2025 to March 2026. South Africa will soon introduce Lenacapavir, a new HIV drug. It is given via injection twice a year and offers six months of protection per dose. Clinical trials have shown Lenacapavir to be highly effective in preventing HIV. South Africa has the highest number of people living with HIV globally, with approximately 8 million cases. The new drug could help reduce new infections, especially among adolescent girls and young women who are disproportionately affected.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.